Literature DB >> 8862851

A participant's observations: preparing DSM-IV.

D Shaffer1.   

Abstract

OBJECTIVE: To provide an overview of the process of creating the DSM-IV from a participant's perspective.
METHOD: Narrative review.
RESULTS: In its attempt to address the perceived weaknesses of both the content and development of the DSM-III and DSM-III-R, the DSM-IV development was based on commissioned reviews for sets of diagnoses, especially designed field trials and a transparent decision-making process.
CONCLUSIONS: Nosology is an ambitious and complicated enterprise. Classification systems must evolve as new empirical evidence is presented. Many of the obstacles faced by the DSM-IV work groups, therefore, may be moot for those formulating DSM-V. The DSM-IV development process was carefully planned, and the profession is indebted to the American Psychiatric Association (APA) for its initiative and effort in producing this system.

Entities:  

Mesh:

Year:  1996        PMID: 8862851     DOI: 10.1177/070674379604100602

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  4 in total

1.  [Serum-based biomarkers for psychiatric disorders].

Authors:  S Bahn; E Schwarz
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

2.  Taxonomy and utility in the diagnostic classification of mental disorders.

Authors:  Spencer C Evans; Michael C Roberts; Jessy Guler; Jared W Keeley; Geoffrey M Reed
Journal:  J Clin Psychol       Date:  2021-02-26

3.  A Prospective Longitudinal Assessment of Medical Records for Diagnostic Substitution among Subjects Diagnosed with a Pervasive Developmental Disorder in the United States.

Authors:  David A Geier; Janet K Kern; Brian S Hooker; Lisa K Sykes; Mark R Geier
Journal:  Front Pediatr       Date:  2015-10-12       Impact factor: 3.418

4.  Low serum vitamin B12 levels among psychiatric patients admitted in Butabika mental hospital in Uganda.

Authors:  Michael Ssonko; Henry Ddungu; Seggane Musisi
Journal:  BMC Res Notes       Date:  2014-02-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.